Patient characteristics
| . | Entire cohort (n = 75) . | Ig reporter identified (n = 57) . | No Ig reporter identified (n = 18) . | P . |
|---|---|---|---|---|
| Average age (years) | 58.3 | 57.5 | 60.8 | .3 |
| Male, n (%) | 44 (58.7) | 34 (59.6) | 10 (55.6) | .79 |
| Female, n (%) | 31 (41.3) | 23 (40.4) | 8 (44.4) | |
| Diagnosis | .23 | |||
| DLBCL, NOS | 54 | 39 | 15 | |
| DLBCL, transformed | 13 | 10 | 3 | |
| PTLD | 8 | 8 | 0 | |
| Stage, n (%) | .0181 | |||
| 1 | 7 (9.3) | 7 (12.3) | 0 (0.0) | |
| 2 | 11 (14.7) | 10 (17.5) | 1 (5.6) | |
| 3 | 8 (10.7) | 3 (5.3) | 5 (27.8) | |
| 4 | 49 (65.3) | 37 (64.9) | 12 (66.7) | |
| IPI, n (%) | .86 | |||
| 0 to 1 | 13 (18.8) | 9 (17.6) | 4 (23.5) | |
| 2 | 23 (33.3) | 17 (33.3) | 6 (35.3) | |
| 3 | 21 (30.4) | 15 (29.4) | 6 (35.3) | |
| 4 to 5 | 12 (17.4) | 10 (19.6) | 2 (11.8) | |
| LDH elevated, n (%) | 34 (48.6) | 29 (53.7) | 5 (31.3) | .11 |
| Cell of origin | ||||
| GCB | 38 (50.7) | 27 (47.4) | 11 (61.1) | .75 |
| Non-GCB | 17 (22.7) | 13 (22.8) | 4 (22.2) | |
| Not available/unclassifiable | 20 (26.7) | 17 (29.8) | 3 (16.7) | |
| Translocations | ||||
| BCL2 | 9/49 (18.4) | 6/35 (17.1) | 3/14 (21.4) | 1 |
| BCL6 | 6/41 (14.6) | 5/29 (17.2) | 1/12 (8.3) | .65 |
| MYC | 8/48 (16.7) | 6/35 (17.1) | 2/13 (15.4) | 1 |
| Treatment | ||||
| DA-EPOCH-R | 22 | |||
| R-CHOP like | 39 | |||
| Modified Magrath | 4 | |||
| Other | 9 | |||
| No treatment | 1 |
| . | Entire cohort (n = 75) . | Ig reporter identified (n = 57) . | No Ig reporter identified (n = 18) . | P . |
|---|---|---|---|---|
| Average age (years) | 58.3 | 57.5 | 60.8 | .3 |
| Male, n (%) | 44 (58.7) | 34 (59.6) | 10 (55.6) | .79 |
| Female, n (%) | 31 (41.3) | 23 (40.4) | 8 (44.4) | |
| Diagnosis | .23 | |||
| DLBCL, NOS | 54 | 39 | 15 | |
| DLBCL, transformed | 13 | 10 | 3 | |
| PTLD | 8 | 8 | 0 | |
| Stage, n (%) | .0181 | |||
| 1 | 7 (9.3) | 7 (12.3) | 0 (0.0) | |
| 2 | 11 (14.7) | 10 (17.5) | 1 (5.6) | |
| 3 | 8 (10.7) | 3 (5.3) | 5 (27.8) | |
| 4 | 49 (65.3) | 37 (64.9) | 12 (66.7) | |
| IPI, n (%) | .86 | |||
| 0 to 1 | 13 (18.8) | 9 (17.6) | 4 (23.5) | |
| 2 | 23 (33.3) | 17 (33.3) | 6 (35.3) | |
| 3 | 21 (30.4) | 15 (29.4) | 6 (35.3) | |
| 4 to 5 | 12 (17.4) | 10 (19.6) | 2 (11.8) | |
| LDH elevated, n (%) | 34 (48.6) | 29 (53.7) | 5 (31.3) | .11 |
| Cell of origin | ||||
| GCB | 38 (50.7) | 27 (47.4) | 11 (61.1) | .75 |
| Non-GCB | 17 (22.7) | 13 (22.8) | 4 (22.2) | |
| Not available/unclassifiable | 20 (26.7) | 17 (29.8) | 3 (16.7) | |
| Translocations | ||||
| BCL2 | 9/49 (18.4) | 6/35 (17.1) | 3/14 (21.4) | 1 |
| BCL6 | 6/41 (14.6) | 5/29 (17.2) | 1/12 (8.3) | .65 |
| MYC | 8/48 (16.7) | 6/35 (17.1) | 2/13 (15.4) | 1 |
| Treatment | ||||
| DA-EPOCH-R | 22 | |||
| R-CHOP like | 39 | |||
| Modified Magrath | 4 | |||
| Other | 9 | |||
| No treatment | 1 |
Characteristics of all patients enrolled in this study. NOS, not otherwise specified; PTLD, posttransplant lymphoproliferative disorder.